Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
July 19 — The White House's cancer “moonshot” initiative will benefit research across disease groups as changes implemented address systemic issues that hamper research progress, a White House aide said July 19.
“Cancer is a great place to start with the culture change because we’ll be able to see the benefit much more quickly than we can in other diseases where we know far less,” Greg Simon, executive director of the White House Cancer Moonshot Task Force, said during a webinar. “But you don’t want to wait until those diseases are as mature as cancer in our knowledge and then change the system. You want to change the system now—first for cancer, and then for everybody.”
Simon made his remarks about three weeks after a national summit on the moonshot, the White House initiative led by Vice President Joe Biden to double the rate of progress in cancer treatments and prevention. One of the key aims of the initiative—which both Simon and Biden have mentioned a number of times—is to change the culture of cancer programs that create roadblocks to research and treatment.
On the research side, Simon has called for changes that improve data sharing, streamline the grants process, make clinical trials more patient-friendly, standardize research nomenclature and standardize tissue collection.
Cancer has a few unique characteristics that make research in this field ripe for culture change, Simon said. With more than 200 types of cancers, some of which have a lot of genetic variants, cancer is “a far more complex set of diseases than any other disease,” he said.
“What we used to think of as cancer really doesn’t exist,” Simon said, adding that tools, knowledge and databases are available in oncology research to accelerate the ability to turn cancer into a chronic disease, cure some cancers and “keep cancer from even being a problem” through prevention and early detection.
“Every improvement we make in this cancer moonshot is not going to go away for Alzheimer’s or cardiovascular disease or diabetes,” he said. “It’s going to help accelerate work in those areas as well.”
With about six months left in President Barack Obama's administration, Simon said, the government task force he's leading is developing a road map of how the next president's administration can build on their work. The road map, which he said will be released by the end of the year, will include recommendations on the culture and programmatic changes in cancer research and clinical care that need to continue.
“We are convinced the moonshot will continue one way or another,” Simon said, adding that “we have no way of knowing what will happen in the next administration. But we do know that there is an enormous public and private sector interest in continuing this work.”
A blue-ribbon panel to inform the scientific direction of the initiative at the National Cancer Institute, part of the National Institutes of Health, will finalize recommendations during a July 20 meeting, panel member Ellen Sigal said during the webinar. Sigal, who is founder of Friends of Cancer Research, said the panel's recommendations will then go to the National Cancer Advisory Board, which is the parent group of the blue ribbon panel. The board will vote on the recommendations and forward them to the White House. The panel is expected to issue its report in August (10 LSLR 14, 7/8/16).
“We're very much on schedule, and we're very excited about the recommendations,” Sigal said.
Bloomberg Philanthropies provides financial support for the moonshot initiative.
To contact the reporter on this story: Jeannie Baumann in Washington firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin email@example.com
More information on the Faster Cures webinar is at http://train.fastercures.org/webinars/show/071916.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)